Arcutis says Phase 2 trial shows Zoryve cream 0.05% clears atopic dermatitis in infants ages 3 to under 24 months

• Arcutis highlighted new ZORYVE clinical and real-world research already presented at EADV and being presented at Fall Clinical.
• Phase 2 infant atopic dermatitis study showed the investigational cream was well tolerated, with rapid skin clearance and fast itch relief.
• Phase 3 psoriasis analyses indicated the foam and cream improved symptoms across scalp and body, with reported quality-of-life gains.
• Regulatory catalyst: FDA review underway to expand ZORYVE cream 0.05% into infants, with a Feb. 23, 2027 PDUFA date.
• Survey and literature review flagged persistent concerns over long-term topical steroid use, supporting demand for non-steroid chronic-control options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090800PRIMZONEFULLFEED9842404) on October 09, 2026, and is solely responsible for the information contained therein.